晚期食管癌免疫治疗研究进展

Advances in Immunotherapy for Advanced Esophageal Cancer

摘要: 食管癌是一种消化道肿瘤，具有高度的侵袭性，晚期疾病的预后差，死亡率高。虽然目前临床上治疗食管癌的药物不断更新，但食管癌患者的总体生存前景仍不容乐观。近些年，随着肿瘤免疫治疗的兴起，食管癌的免疫治疗引起了人们广泛关注，尤其是关于免疫检查点抑制剂在食管癌治疗中的应用，显著改善了食管癌患者的预后。免疫治疗为多种肿瘤患者提供了新的治疗选择。围绕PD-1/PD-L1抑制剂在食管癌中作用机制及疗效的临床试验也在陆续开展，随着更多临床试验的结果公布，将食管癌免疫治疗带入一个新的时代。作为一种新的有效的癌症治疗手段，免疫治疗在食管癌治疗中具有广阔的应用前景。对于患者来说，将化疗与免疫抑制剂结合使用是安全有效的，可同时提高抗肿瘤免疫反应。本文就食管癌免疫治疗进展作一简要概述。

Abstract: Esophageal cancer is a kind of digestive tract tumor, which is highly invasive. The prognosis of ad-vanced diseases is poor and the mortality is high. Although the drugs for the treatment of esopha-geal cancer are constantly updated, the overall survival prospect of esophageal cancer patients is still not optimistic. In recent years, with the rise of tumor immunotherapy, the immunotherapy of esophageal cancer has attracted extensive attention, especially about the application of immune checkpoint inhibitors in the treatment of esophageal cancer, which has significantly improved the prognosis of esophageal cancer patients. Immunotherapy provides a new treatment option for a va-riety of tumor patients. Clinical trials focusing on the mechanism and efficacy of Pd-1/Pd-L1 inhibi-tors in esophageal cancer are also being carried out in succession. With the publication of the re-sults of more clinical trials, the immunotherapy of esophageal cancer will enter a new era. As a new and effective cancer treatment, immunotherapy has a broad application prospect in the treatment of esophageal cancer. For patients, the combination of chemotherapy and immunosuppressants is safe and effective, and can improve the anti-tumor immune response at the same time.